Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method

Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced/metastatic CRC (mCRC). Th...

Full description

Saved in:
Bibliographic Details
Published inSouth Asian journal of cancer
Main Authors Ramaswamy, Anant, Srinivas, Sujay, Lavingia, Viraj, Boppana, Mounika, Vora, Chakor, Singh, Randeep, Krishna, M. Vamshi, Vora, Amish, Mullapally, Sujith Kumar, Bhargava, Prabhat, Maka, Vinayak, Goyal, Gautam, Agarwala, Vivek, Karpe, Ashay, Mirani, Jimmy, Shankar, S Krupa, Mandal, Tanmoy Kumar, Mishra, Sourav Kumar, Syed, Nisar Ahmad, Sharma, Atul, Das, Shasanka Sekhar, Panda, Soumya Surath, Mondal, Pradip Kumar, Kumar, Amit, Patil, Shekar, Pinninti, Rakesh, John, Ajoy Oommen, Bohra, Murtaza, Rajendranath, Rejiv, Das, Sudeep, Goyal, Sumit, P., Rakesh M., Rathnam, Krishnakumar, Patel, Amol, Dhabhar, Boman, Thanky, Aditi, Doshi, Vipul, Kapoor, Akhil, Shetty, Nishitha, Paul, Davinder, George, Jacob, Baheti, Akshay D., Krishnatry, Rahul, Ostwal, Vikas
Format Journal Article
LanguageEnglish
Published Thieme Medical and Scientific Publishers Pvt. Ltd 26.05.2025
Subjects
India specific
metastatic colorectal cancer
modified Delphi consensus
Online AccessGet full text
ISSN2278-330X
2278-4306
DOI10.1055/s-0045-1809380

Cover

Abstract Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced/metastatic CRC (mCRC). This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by medical oncologists treating mCRC. A panel of 38 medical oncologists held a meeting in February 2023 and reviewed the evidence available for the management of mCRC. The meeting concentrated on the recognition and management of mCRC with a focus on systemic therapeutic approaches. A literature review of these aspects of management leads to the formation of consensus statements with the level of evidence and grades of recommendation. Statements were evaluated by the modified Delphi method. The panel comprising 38 experts formulated 51 consensus statements with regard to the management of mCRC, including oligometastatic CRC, unresectable CRC, as well as various systemic therapeutic options. Resource-constrained scenarios, specifically with regard to the economic constraints and availability of drugs in India, were evaluated as part of the statements. Our consensus statements offer practical, yet evidence-based management guidelines for treating mCRC in the Indian context. Stratifying and recommending treatment options in a resource-constrained scenario is an important aspect of these statements.
AbstractList Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced/metastatic CRC (mCRC). This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by medical oncologists treating mCRC. A panel of 38 medical oncologists held a meeting in February 2023 and reviewed the evidence available for the management of mCRC. The meeting concentrated on the recognition and management of mCRC with a focus on systemic therapeutic approaches. A literature review of these aspects of management leads to the formation of consensus statements with the level of evidence and grades of recommendation. Statements were evaluated by the modified Delphi method. The panel comprising 38 experts formulated 51 consensus statements with regard to the management of mCRC, including oligometastatic CRC, unresectable CRC, as well as various systemic therapeutic options. Resource-constrained scenarios, specifically with regard to the economic constraints and availability of drugs in India, were evaluated as part of the statements. Our consensus statements offer practical, yet evidence-based management guidelines for treating mCRC in the Indian context. Stratifying and recommending treatment options in a resource-constrained scenario is an important aspect of these statements.
Author Singh, Randeep
Patil, Shekar
Goyal, Sumit
Lavingia, Viraj
Ramaswamy, Anant
Bhargava, Prabhat
Kapoor, Akhil
Goyal, Gautam
Das, Shasanka Sekhar
Ostwal, Vikas
Doshi, Vipul
Syed, Nisar Ahmad
Boppana, Mounika
Maka, Vinayak
Mishra, Sourav Kumar
Mandal, Tanmoy Kumar
Das, Sudeep
Krishnatry, Rahul
Shankar, S Krupa
Panda, Soumya Surath
Vora, Amish
Agarwala, Vivek
Rajendranath, Rejiv
Bohra, Murtaza
Thanky, Aditi
P., Rakesh M.
Krishna, M. Vamshi
Srinivas, Sujay
Mirani, Jimmy
Mondal, Pradip Kumar
Dhabhar, Boman
John, Ajoy Oommen
Rathnam, Krishnakumar
Karpe, Ashay
Mullapally, Sujith Kumar
Baheti, Akshay D.
Shetty, Nishitha
Sharma, Atul
Patel, Amol
Kumar, Amit
George, Jacob
Pinninti, Rakesh
Vora, Chakor
Paul, Davinder
Author_xml – sequence: 1
  givenname: Anant
  surname: Ramaswamy
  fullname: Ramaswamy, Anant
– sequence: 2
  givenname: Sujay
  surname: Srinivas
  fullname: Srinivas, Sujay
– sequence: 3
  givenname: Viraj
  orcidid: 0000-0003-1981-2693
  surname: Lavingia
  fullname: Lavingia, Viraj
– sequence: 4
  givenname: Mounika
  surname: Boppana
  fullname: Boppana, Mounika
– sequence: 5
  givenname: Chakor
  surname: Vora
  fullname: Vora, Chakor
– sequence: 6
  givenname: Randeep
  surname: Singh
  fullname: Singh, Randeep
– sequence: 7
  givenname: M. Vamshi
  surname: Krishna
  fullname: Krishna, M. Vamshi
– sequence: 8
  givenname: Amish
  surname: Vora
  fullname: Vora, Amish
– sequence: 9
  givenname: Sujith Kumar
  orcidid: 0000-0003-2932-2663
  surname: Mullapally
  fullname: Mullapally, Sujith Kumar
– sequence: 10
  givenname: Prabhat
  orcidid: 0000-0002-6440-2186
  surname: Bhargava
  fullname: Bhargava, Prabhat
– sequence: 11
  givenname: Vinayak
  surname: Maka
  fullname: Maka, Vinayak
– sequence: 12
  givenname: Gautam
  surname: Goyal
  fullname: Goyal, Gautam
– sequence: 13
  givenname: Vivek
  orcidid: 0000-0003-1381-0320
  surname: Agarwala
  fullname: Agarwala, Vivek
– sequence: 14
  givenname: Ashay
  surname: Karpe
  fullname: Karpe, Ashay
– sequence: 15
  givenname: Jimmy
  surname: Mirani
  fullname: Mirani, Jimmy
– sequence: 16
  givenname: S Krupa
  surname: Shankar
  fullname: Shankar, S Krupa
– sequence: 17
  givenname: Tanmoy Kumar
  surname: Mandal
  fullname: Mandal, Tanmoy Kumar
– sequence: 18
  givenname: Sourav Kumar
  surname: Mishra
  fullname: Mishra, Sourav Kumar
– sequence: 19
  givenname: Nisar Ahmad
  surname: Syed
  fullname: Syed, Nisar Ahmad
– sequence: 20
  givenname: Atul
  surname: Sharma
  fullname: Sharma, Atul
– sequence: 21
  givenname: Shasanka Sekhar
  surname: Das
  fullname: Das, Shasanka Sekhar
– sequence: 22
  givenname: Soumya Surath
  orcidid: 0000-0003-2190-1927
  surname: Panda
  fullname: Panda, Soumya Surath
– sequence: 23
  givenname: Pradip Kumar
  surname: Mondal
  fullname: Mondal, Pradip Kumar
– sequence: 24
  givenname: Amit
  surname: Kumar
  fullname: Kumar, Amit
– sequence: 25
  givenname: Shekar
  surname: Patil
  fullname: Patil, Shekar
– sequence: 26
  givenname: Rakesh
  surname: Pinninti
  fullname: Pinninti, Rakesh
– sequence: 27
  givenname: Ajoy Oommen
  surname: John
  fullname: John, Ajoy Oommen
– sequence: 28
  givenname: Murtaza
  surname: Bohra
  fullname: Bohra, Murtaza
– sequence: 29
  givenname: Rejiv
  surname: Rajendranath
  fullname: Rajendranath, Rejiv
– sequence: 30
  givenname: Sudeep
  surname: Das
  fullname: Das, Sudeep
– sequence: 31
  givenname: Sumit
  surname: Goyal
  fullname: Goyal, Sumit
– sequence: 32
  givenname: Rakesh M.
  surname: P.
  fullname: P., Rakesh M.
– sequence: 33
  givenname: Krishnakumar
  surname: Rathnam
  fullname: Rathnam, Krishnakumar
– sequence: 34
  givenname: Amol
  orcidid: 0000-0002-9516-8935
  surname: Patel
  fullname: Patel, Amol
– sequence: 35
  givenname: Boman
  surname: Dhabhar
  fullname: Dhabhar, Boman
– sequence: 36
  givenname: Aditi
  surname: Thanky
  fullname: Thanky, Aditi
– sequence: 37
  givenname: Vipul
  surname: Doshi
  fullname: Doshi, Vipul
– sequence: 38
  givenname: Akhil
  orcidid: 0000-0001-6006-2631
  surname: Kapoor
  fullname: Kapoor, Akhil
– sequence: 39
  givenname: Nishitha
  surname: Shetty
  fullname: Shetty, Nishitha
– sequence: 40
  givenname: Davinder
  surname: Paul
  fullname: Paul, Davinder
– sequence: 41
  givenname: Jacob
  surname: George
  fullname: George, Jacob
– sequence: 42
  givenname: Akshay D.
  surname: Baheti
  fullname: Baheti, Akshay D.
– sequence: 43
  givenname: Rahul
  orcidid: 0000-0003-4511-7782
  surname: Krishnatry
  fullname: Krishnatry, Rahul
– sequence: 44
  givenname: Vikas
  orcidid: 0000-0002-0067-4748
  surname: Ostwal
  fullname: Ostwal, Vikas
BookMark eNo9kUtLBDEQhIMoqKtXz_kDs3Y2yUzmuIyvBUVBBW-hJw-NzCaSjILgj3fHXTx10131QVHHZD-m6Ag5YzBnIOV5qQCErJiClivYI0eLRaMqwaHe3-2cw8shOS3lHQAYcK5adkR-uhSLi-Wz0McRR7d2cSzUp0y7IcRgcKAPGc0YjKMh0qX9wmicPb9zI5aNIRjapSFlZ8aNtJueuUzKVbQB6XMJ8ZUivUs2-OAsvXDDx1ugG_tbsifkwONQ3OluzsjT1eVTd1Pd3l-vuuVtZbiAsfICgckafKOM9Kb2zYJxaxBbgQtZG1fzpq9r0TfMetUb0TYOwUrbGNl7xmdktcXahO_6I4c15m-dMOi_Q8qvGvMmyeC0tY0EVZteeSW8l-gFKGNb6YRngk2s-ZZlciolO__PY6CnJnTRUxN61wT_BVx5fuE
Cites_doi 10.1007/s13244-010-0037-4
10.1148/radiology.211.1.r99ap35215
10.1200/JCO.22.01015
10.1200/JCO.2010.33.5091
10.1200/JCO.22.01690
10.1097/00000658-199909000-00004
10.1016/S1470-2045(11)70199-1
10.5858/arpa.2011-0035-RA
10.1016/S1470-2045(15)00122-9
10.1002/bjs.7096
10.1016/S1470-2045(18)30140-2
10.1016/S1470-2045(15)00042-X
10.1046/j.1463-1318.2003.00518.x
10.1056/NEJMoa032709
10.1016/j.clcc.2016.02.007
10.1200/PO.22.00306
10.1016/S1470-2045(19)30272-4
10.1056/NEJM200502173520723
10.1200/JCO.2004.05.113
10.1093/annonc/mdx119
10.1159/000346328
10.1093/annonc/mdw136
10.1002/ijc.25555
10.1001/jamaoncol.2021.4158
10.1200/JCO.2002.08.015
10.1200/JCO.2023.41.16_suppl.TPS3627
10.1245/s10434-007-9626-y
10.1056/NEJMoa1305275
10.1016/j.crad.2010.01.024
10.1200/JCO.2007.14.9930
10.1093/annonc/mdh305
10.1200/JCO.2002.12.075
10.1016/S0140-6736(11)60613-2
10.1016/S1470-2045(10)70130-3
10.1200/JCO.2009.27.6055
10.1200/JCO.2006.09.2684
10.3390/cancers13225750
10.18632/oncotarget.21169
10.3393/ac.2019.11.13
10.1200/JCO.2006.09.6305
10.1158/1078-0432.CCR-15-0526
10.1200/JCO.21.01332
10.1200/JCO.20.02447
10.1056/NEJMc0904160
10.1016/S0140-6736(98)03085-2
10.1093/annonc/mds053
10.1016/j.ejca.2011.04.024
10.3390/biomedicines11041032
10.1200/JCO.2009.23.4344
10.1016/S1470-2045(15)70127-0
10.1093/annonc/mdn370
10.1136/esmoopen-2018-000353
10.1200/JCO.2004.11.037
10.3390/cancers12092432
10.1093/annonc/mdv197
10.1200/JCO.2012.45.3258
10.1016/j.ejca.2012.02.057
10.1093/annonc/mdu100
10.1093/annonc/mdy281.015
10.1200/JCO.2009.27.7723
10.1007/s00330-018-5469-0
10.1634/theoncologist.2019-0541
10.1200/JCO.2018.36.4_suppl.789
10.1016/S0140-6736(11)60399-1
10.1038/bjc.2016.309
10.3109/00365521.2011.574732
10.1016/S0140-6736(21)01789-X
10.1056/NEJMoa1500596
10.1093/annonc/mdx125
10.1200/JCO.2007.14.9898
10.1186/s12885-021-08398-z
10.1016/S0140-6736(07)61087-3
10.1016/j.ejca.2020.08.009
10.1053/j.sult.2005.04.005
10.1001/jama.2023.4428
10.21037/jgo.2016.03.02
10.4103/cmrp.cmrp_65_20
10.1016/S1470-2045(16)00150-9
10.1200/JCO.2020.38.4_suppl.116
10.6004/jnccn.2018.7277
10.1016/S1470-2045(21)00086-3
10.1200/JCO.2008.18.0786
10.1097/SLA.0b013e31815c29ff
10.1016/S1470-2045(22)00197-8
10.1200/JCO.2005.03.0106
10.1200/JCO.2005.07.113
10.1038/s41598-017-11048-9
10.1016/j.radonc.2020.02.008
10.1200/JCO.2024.42.3_suppl.LBA768
10.1200/JCO.2014.59.7633
10.1200/JCO.2020.38.15_suppl.e16084
10.1186/s12885-015-1701-3
10.1038/s41577-020-0306-5
10.1634/theoncologist.2013-0107
10.4103/2278-330X.195338
10.1001/jamaoncol.2016.4227
10.1016/S1470-2045(23)00572-7
10.1016/j.critrevonc.2017.08.006
10.1007/s13193-017-0655-0
10.1200/JCO.2018.36.4_suppl.726
10.1002/cpt.911
10.1016/S1470-2045(16)30269-8
10.1056/NEJMoa1714448
10.1200/jco.2014.32.3_suppl.lba387
10.1038/sj.bjc.6603011
10.18632/oncotarget.7193
10.1016/S1470-2045(13)70154-2
10.1055/s-0041-1736203
10.3389/fonc.2023.1178772
10.1080/02656736.2021.1923836
10.1007/s00330-019-06369-4
10.1016/S1470-2045(23)00150-X
10.1016/S1470-2045(12)70477-1
10.1016/S0002-9610(99)00187-7
10.1200/JCO.2003.11.126
10.3389/fonc.2023.1268783
10.1093/annonc/mdx175
10.1093/annonc/mdx514
10.1016/S0140-6736(14)62004-3
10.1200/JCO.20.02088
10.1093/annonc/mdv012
10.1016/S0140-6736(12)61900-X
10.1007/s11604-017-0622-2
10.7326/0003-4819-113-10-779
10.4103/0971-5851.142031
10.1148/radiology.206.3.9494497
10.1080/00365520701745842
10.2147/DDDT.S85567
10.1056/NEJMoa0808268
10.1200/JCO.2006.09.0928
10.1200/JCO.23.02722
10.1200/JCO.2006.08.1620
10.1200/JCO.2007.14.7116
10.1056/NEJMoa032691
10.1016/S1470-2045(19)30827-7
10.1016/S1470-2045(23)00219-X
10.1016/S1470-2045(13)70163-3
10.1097/PPO.0000000000000438
10.1056/NEJMoa0804385
10.1001/jamaoncol.2016.3797
10.1007/s12032-014-0325-9
10.1016/S1470-2045(14)70118-4
10.1016/S1470-2045(20)30599-4
10.1016/S1470-2045(15)70156-7
10.1093/annonc/mdr623
10.1016/j.annonc.2022.10.003
10.1016/S0140-6736(98)02309-5
10.1002/ijc.32110
10.3390/cancers15061827
10.1056/NEJMoa2017699
10.1200/JCO.2016.34.15_suppl.3517
10.1016/S1470-2045(13)70447-9
10.3748/wjg.v22.i20.4891
10.1016/S1470-2045(18)30904-5
10.1200/JCO.2006.09.8467
10.1634/theoncologist.2016-0462
10.1001/jamaoncol.2017.3695
10.1126/scitranslmed.3002442
10.1200/JCO.2017.75.2931
10.3322/caac.21660
10.1158/1078-0432.CCR-15-1678
10.3109/07357907.2015.1104689
10.1086/656735
10.1016/S0140-6736(07)61086-1
10.1016/j.ejca.2016.10.007
10.1056/NEJMoa1414325
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.1055/s-0045-1809380
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2278-4306
ExternalDocumentID oai_doaj_org_article_dd75086cb8f84ff5af408cd95e4f1411
10_1055_s_0045_1809380
GroupedDBID 0R~
0U6
5VS
AAYXX
ACGFS
ADBBV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
HYE
IAO
IHR
KQ8
OK1
PGMZT
RPM
RTC
ADRAZ
AHRAW
H13
IPNFZ
ITC
M48
RIG
ID FETCH-LOGICAL-c340t-f4a01560f78c5fc6f7213dcaa94a256ce637b664b71df8bc497ea0d5d7c5bf13
IEDL.DBID DOA
ISSN 2278-330X
IngestDate Wed Aug 27 01:20:52 EDT 2025
Sun Jul 06 05:09:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License https://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c340t-f4a01560f78c5fc6f7213dcaa94a256ce637b664b71df8bc497ea0d5d7c5bf13
ORCID 0000-0003-1381-0320
0000-0003-1981-2693
0000-0003-2932-2663
0000-0003-2190-1927
0000-0002-9516-8935
0000-0001-6006-2631
0000-0003-4511-7782
0000-0002-0067-4748
0000-0002-6440-2186
OpenAccessLink https://doaj.org/article/dd75086cb8f84ff5af408cd95e4f1411
ParticipantIDs doaj_primary_oai_doaj_org_article_dd75086cb8f84ff5af408cd95e4f1411
crossref_primary_10_1055_s_0045_1809380
PublicationCentury 2000
PublicationDate 2025-05-26
PublicationDateYYYYMMDD 2025-05-26
PublicationDate_xml – month: 05
  year: 2025
  text: 2025-05-26
  day: 26
PublicationDecade 2020
PublicationTitle South Asian journal of cancer
PublicationYear 2025
Publisher Thieme Medical and Scientific Publishers Pvt. Ltd
Publisher_xml – name: Thieme Medical and Scientific Publishers Pvt. Ltd
References M Peeters (ref38) 2015; 21
K PS Raghav (ref54) 2016; 34
A Falcone (ref70) 2002; 20
M T Seymour (ref45) 2013; 14
F Maindrault-Goebel (ref161) 2004; 15
F Loupakis (ref91) 2018; 36
D Arnold (ref92) 2017; 28
I Mohamad (ref126) 2022; 39
N E Kemeny (ref11) 2005; 352
T Andre (ref112) 2024; 42
O Israel (ref16) 2007; 48
B Görgec (ref23) 2024; 25
F Ciardiello (ref144) 2016; 27
R J Mayer (ref154) 2015; 372
U Amstutz (ref166) 2018; 103
J Tabernero (ref162) 2021; 39
J Tol (ref40) 2009; 360
M Nakamura (ref153) 2020; 38
S Dighe (ref13) 2010; 97
A Bayle (ref58) 2021; 13
M Peeters (ref141) 2010; 28
T S Bekaii-Saab (ref151) 2019; 20
A Takashima (ref82) 2024; 42
M Ye (ref49) 2023; 13
W De Roock (ref39) 2010; 11
G Brown (ref30) 1999; 211
T W Kim (ref158) 2016; 115
A Ramaswamy (ref6) 2022; 11
E Van Cutsem (ref157) 2007; 25
K B Geiersbach (ref48) 2011; 135
A R Khan (ref10) 2010; 51
G Fiorentini (ref124) 2012; 32
Y Fong (ref117) 1999; 230
B Sirohi (ref9) 2014; 35
S Asthana (ref2) 2021; 11
F Di Nicolantonio (ref44) 2008; 26
S Tejpar (ref88) 2017; 3
C Tournigand (ref64) 2004; 22
S R Rafaelsen (ref26) 2008; 43
A Drilon (ref59) 2018; 378
S Siena (ref102) 2021; 22
M JG Bond (ref121) 2023; 24
M L Rothenberg (ref133) 2008; 19
J Li (ref150) 2015; 16
Y Fong (ref19) 1999; 178
J Souglakos (ref71) 2002; 20
A Grothey (ref72) 2004; 22
J W Holch (ref85) 2017; 70
K Sivesgaard (ref20) 2018; 28
M Peeters (ref34) 2014; 32
D Li (ref78) 2021; 7
S Hegewisch-Becker (ref106) 2015; 16
F Meric-Bernstam (ref56) 2019; 20
M T Seymour (ref81) 2011; 377
M Suenaga (ref160) 2015; 9
S J Clarke (ref130) 2011; 47
K J Barnum (ref115) 2020; 26
P Rougier (ref128) 1998; 352
V Mathew Thomas (ref3) 2020; 38
L B Saltz (ref97) 2008; 26
P Pfeiffer (ref155) 2020; 21
K Yonesaka (ref53) 2011; 3
T André (ref52) 2020; 383
E Díaz-Rubio (ref66) 2007; 25
R Porschen (ref67) 2007; 25
M J Lahaye (ref27) 2005; 26
M Koopman (ref62) 2007; 370
Y Kanemitsu (ref123) 2021; 39
B J Giantonio (ref137) 2007; 25
J Vidal (ref60) 2017; 28
M Antonio (ref79) 2017; 22
T Ruers (ref125) 2012; 23
T André (ref118) 2004; 350
M T Seymour (ref61) 2007; 370
B Chibaudel (ref104) 2009; 27
C Hall (ref164) 2019; 35
A Shahrokni (ref77) 2019; 17
N Boeckx (ref89) 2017; 28
E Van Cutsem (ref35) 2011; 29
V Sharma (ref5) 2021; 21
V M Patil (ref167) 2016; 5
C Bokemeyer (ref46) 2012; 48
D Cunningham (ref98) 2013; 14
L HJ Simkens (ref105) 2015; 385
M L Schnitzer (ref15) 2020; 12
C S Karapetis (ref32) 2008; 359
A Passardi (ref142) 2017; 7
R Cao (ref136) 2015; 32
S Kopetz (ref95) 2023; 41
J H Strickler (ref57) 2023; 24
C Tournigand (ref103) 2006; 24
M R Torkzad (ref25) 2010; 1
S Stintzing (ref122) 2016; 17
S Dighe (ref14) 2010; 65
J Tabernero (ref139) 2015; 16
D T Le (ref47) 2015; 372
J C Dudley (ref50) 2016; 22
G Colucci (ref65) 2005; 23
J Bennouna (ref135) 2013; 14
T S Maughan (ref36) 2011; 377
H Xie (ref163) 2023; 13
T J Price (ref159) 2014; 15
T Aparicio (ref107) 2018; 36
T Masuishi (ref152) 2018; 29
Q Feng (ref145) 2016; 7
H L Wong (ref90) 2016; 15
J Tie (ref42) 2011; 128
J Souglakos (ref74) 2006; 94
F Quénet (ref127) 2021; 22
H Hurwitz (ref96) 2004; 350
N C Tebbutt (ref99) 2010; 28
C Cremolini (ref76) 2015; 16
R Gupta (ref101) 2022; 6
A Ottaiano (ref116) 2023; 15
D Arnold (ref140) 2017; 28
H I Hurwitz (ref100) 2013; 18
J Y Douillard (ref37) 2013; 369
S Iwamoto (ref138) 2015; 26
F GM Taylor (ref29) 2014; 32
D Cunningham (ref129) 1998; 352
R Moretto (ref120) 2020; 139
H Sung (ref1) 2021; 71
S G Mohile (ref80) 2021; 398
F Petrelli (ref84) 2017; 3
R P Marques (ref75) 2017; 118
A Grothey (ref149) 2013; 381
J Taieb (ref86) 2018; 4
D P Modest (ref109) 2019; 145
H Fujii (ref156) 2020; 25
L A Diaz Jr (ref111) 2022; 23
V K Morris (ref8) 2023; 41
C J Zech (ref21) 2020; 30
B Nordlinger (ref119) 2013; 14
A D Waldman (ref169) 2020; 20
H Abdel-Nabi (ref17) 1998; 206
D Ippolito (ref24) 2016; 22
M L Rothenberg (ref132) 2003; 21
Y Guo (ref69) 2016; 34
J Tol (ref41) 2009; 361
R G Amado (ref33) 2008; 26
A Sartore-Bianchi (ref55) 2016; 17
D Santini (ref148) 2012; 23
F Meriggi (ref170) 2023; 11
R H Xu (ref131) 2018; 19
D P Modest (ref110) 2022; 40
P S Patil (ref4) 2017; 8
J Cassidy (ref68) 2008; 26
N Asato (ref22) 2017; 35
V M Patil (ref113) 2023; 41
A Cervantes (ref7) 2023; 34
R M Goldberg (ref143) 2018; 3
J A Bufill (ref83) 1990; 113
J Watanabe (ref93) 2023; 329
C SR Nahas (ref18) 2008; 15
X Liu (ref147) 2015; 15
M Ducreux (ref63) 2011; 12
A Falcone (ref73) 2007; 25
K R Jethwa (ref114) 2020; 146
R Chamlou (ref31) 2007; 246
R GH Beets-Tan (ref28) 2003; 5
A Mohamed (ref108) 2018; 36
A M Leufkens (ref12) 2011; 46
M G Fakih (ref43) 2015; 33
J Goldstein (ref51) 2014; 25
A Sahu (ref168) 2016; 7
A A Fora (ref146) 2013; 84
M E Salem (ref87) 2017; 8
G Masi (ref134) 2015; 26
References_xml – volume: 1
  start-page: 245
  issue: 04
  year: 2010
  ident: ref25
  article-title: Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review
  publication-title: Insights Imaging
  doi: 10.1007/s13244-010-0037-4
– volume: 211
  start-page: 215
  issue: 01
  year: 1999
  ident: ref30
  article-title: Rectal carcinoma: thin-section MR imaging for staging in 28 patients
  publication-title: Radiology
  doi: 10.1148/radiology.211.1.r99ap35215
– volume: 41
  start-page: 222
  issue: 02
  year: 2023
  ident: ref113
  article-title: Low-dose immunotherapy in head and neck cancer: a randomized study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.22.01015
– volume: 29
  start-page: 2011
  issue: 15
  year: 2011
  ident: ref35
  article-title: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.33.5091
– volume: 41
  start-page: 678
  issue: 03
  year: 2023
  ident: ref8
  article-title: Treatment of metastatic colorectal cancer: ASCO guideline
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.22.01690
– volume: 230
  start-page: 309
  issue: 03
  year: 1999
  ident: ref117
  article-title: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases
  publication-title: Ann Surg
  doi: 10.1097/00000658-199909000-00004
– volume: 12
  start-page: 1032
  issue: 11
  year: 2011
  ident: ref63
  article-title: Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70199-1
– volume: 135
  start-page: 1269
  issue: 10
  year: 2011
  ident: ref48
  article-title: Microsatellite instability and colorectal cancer
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2011-0035-RA
– volume: 16
  start-page: 1306
  issue: 13
  year: 2015
  ident: ref76
  article-title: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00122-9
– volume: 97
  start-page: 1407
  issue: 09
  year: 2010
  ident: ref13
  article-title: Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer
  publication-title: Br J Surg
  doi: 10.1002/bjs.7096
– volume: 19
  start-page: 660
  issue: 05
  year: 2018
  ident: ref131
  article-title: Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30140-2
– volume: 16
  start-page: 1355
  issue: 13
  year: 2015
  ident: ref106
  article-title: Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)00042-X
– volume: 5
  start-page: 392
  issue: 05
  year: 2003
  ident: ref28
  article-title: MRI in rectal cancer: the T stage and circumferential resection margin
  publication-title: Colorectal Dis
  doi: 10.1046/j.1463-1318.2003.00518.x
– volume: 350
  start-page: 2343
  issue: 23
  year: 2004
  ident: ref118
  article-title: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa032709
– volume: 15
  start-page: e9
  issue: 02
  year: 2016
  ident: ref90
  article-title: Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2016.02.007
– volume: 6
  start-page: e2200306
  issue: 06
  year: 2022
  ident: ref101
  article-title: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2/3 mutations: results from the TAPUR study
  publication-title: JCO Precis Oncol
  doi: 10.1200/PO.22.00306
– volume: 20
  start-page: 1070
  issue: 08
  year: 2019
  ident: ref151
  article-title: Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30272-4
– volume: 352
  start-page: 734
  issue: 07
  year: 2005
  ident: ref11
  article-title: Hepatic arterial infusion after liver resection
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200502173520723
– volume: 22
  start-page: 229
  issue: 02
  year: 2004
  ident: ref64
  article-title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.05.113
– volume: 28
  start-page: 1862
  issue: 08
  year: 2017
  ident: ref89
  article-title: Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx119
– volume: 84
  start-page: 210
  issue: 04
  year: 2013
  ident: ref146
  article-title: A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan
  publication-title: Oncology
  doi: 10.1159/000346328
– volume: 27
  start-page: 1055
  issue: 06
  year: 2016
  ident: ref144
  article-title: Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw136
– volume: 128
  start-page: 2075
  issue: 09
  year: 2011
  ident: ref42
  article-title: Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25555
– volume: 7
  start-page: e214158
  issue: 11
  year: 2021
  ident: ref78
  article-title: Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2021.4158
– volume: 20
  start-page: 2651
  issue: 11
  year: 2002
  ident: ref71
  article-title: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.08.015
– volume: 41
  start-page: TPS3627
  year: 2023
  ident: ref95
  article-title: BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2023.41.16_suppl.TPS3627
– volume: 15
  start-page: 704
  issue: 03
  year: 2008
  ident: ref18
  article-title: Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-007-9626-y
– volume: 369
  start-page: 1023
  issue: 11
  year: 2013
  ident: ref37
  article-title: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1305275
– volume: 65
  start-page: 708
  issue: 09
  year: 2010
  ident: ref14
  article-title: Diagnostic precision of CT in local staging of colon cancers: a meta-analysis
  publication-title: Clin Radiol
  doi: 10.1016/j.crad.2010.01.024
– volume: 26
  start-page: 2013
  issue: 12
  year: 2008
  ident: ref97
  article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.9930
– volume: 15
  start-page: 1210
  issue: 08
  year: 2004
  ident: ref161
  article-title: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdh305
– volume: 20
  start-page: 4006
  issue: 19
  year: 2002
  ident: ref70
  article-title: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.12.075
– volume: 377
  start-page: 2103
  year: 2011
  ident: ref36
  article-title: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60613-2
– volume: 11
  start-page: 753
  issue: 08
  year: 2010
  ident: ref39
  article-title: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70130-3
– volume: 28
  start-page: 4706
  issue: 31
  year: 2010
  ident: ref141
  article-title: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.6055
– volume: 25
  start-page: 4217
  issue: 27
  year: 2007
  ident: ref67
  article-title: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.2684
– volume: 13
  start-page: 5750
  issue: 22
  year: 2021
  ident: ref58
  article-title: Next-generation sequencing targeted panel in routine care for metastatic colon cancers
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13225750
– volume: 8
  start-page: 86356
  issue: 49
  year: 2017
  ident: ref87
  article-title: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.21169
– volume: 35
  start-page: 294
  issue: 06
  year: 2019
  ident: ref164
  article-title: A review of the role of carcinoembryonic antigen in clinical practice
  publication-title: Ann Coloproctol
  doi: 10.3393/ac.2019.11.13
– volume: 25
  start-page: 1539
  issue: 12
  year: 2007
  ident: ref137
  article-title: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.6305
– volume: 21
  start-page: 5469
  issue: 24
  year: 2015
  ident: ref38
  article-title: Analysis of KRAS/NRAS mutations in a Phase III Study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0526
– volume: 40
  start-page: 72
  issue: 01
  year: 2022
  ident: ref110
  article-title: Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.01332
– volume: 39
  start-page: 1098
  issue: 10
  year: 2021
  ident: ref123
  article-title: Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.02447
– volume: 361
  start-page: 98
  issue: 01
  year: 2009
  ident: ref41
  article-title: BRAF mutation in metastatic colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc0904160
– volume: 352
  start-page: 1407
  year: 1998
  ident: ref128
  article-title: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)03085-2
– volume: 23
  start-page: 2619
  issue: 10
  year: 2012
  ident: ref125
  article-title: Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mds053
– volume: 47
  start-page: 1826
  issue: 12
  year: 2011
  ident: ref130
  article-title: Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2011.04.024
– volume: 11
  start-page: 1032
  issue: 04
  year: 2023
  ident: ref170
  article-title: Low-dose immunotherapy: Is it just an illusion?
  publication-title: Biomedicines
  doi: 10.3390/biomedicines11041032
– volume: 27
  start-page: 5727
  issue: 34
  year: 2009
  ident: ref104
  article-title: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.4344
– volume: 16
  start-page: 499
  issue: 05
  year: 2015
  ident: ref139
  article-title: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)70127-0
– volume: 19
  start-page: 1720
  issue: 10
  year: 2008
  ident: ref133
  article-title: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdn370
– volume: 3
  start-page: e000353
  issue: 04
  year: 2018
  ident: ref143
  article-title: Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2018-000353
– volume: 22
  start-page: 1209
  issue: 07
  year: 2004
  ident: ref72
  article-title: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.11.037
– volume: 12
  start-page: 2432
  issue: 09
  year: 2020
  ident: ref15
  article-title: Follow-up 18F-FDG PET/CT versus contrast-enhanced CT after ablation of liver metastases of colorectal carcinoma - a cost-effectiveness analysis
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12092432
– volume: 26
  start-page: 1427
  issue: 07
  year: 2015
  ident: ref138
  article-title: FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv197
– volume: 32
  start-page: 34
  issue: 01
  year: 2014
  ident: ref29
  article-title: Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.3258
– volume: 48
  start-page: 1466
  issue: 10
  year: 2012
  ident: ref46
  article-title: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2012.02.057
– volume: 25
  start-page: 1032
  issue: 05
  year: 2014
  ident: ref51
  article-title: Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu100
– volume: 29
  start-page: viii156
  year: 2018
  ident: ref152
  article-title: Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy281.015
– volume: 28
  start-page: 3191
  issue: 19
  year: 2010
  ident: ref99
  article-title: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.7723
– volume: 28
  start-page: 4735
  issue: 11
  year: 2018
  ident: ref20
  article-title: Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation
  publication-title: Eur Radiol
  doi: 10.1007/s00330-018-5469-0
– volume: 25
  start-page: e469
  issue: 03
  year: 2020
  ident: ref156
  article-title: Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2019-0541
– volume: 36
  start-page: 789
  year: 2018
  ident: ref108
  article-title: Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.4_suppl.789
– volume: 377
  start-page: 1749
  year: 2011
  ident: ref81
  article-title: Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60399-1
– volume: 115
  start-page: 1206
  issue: 10
  year: 2016
  ident: ref158
  article-title: A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.309
– volume: 46
  start-page: 887
  year: 2011
  ident: ref12
  article-title: Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review
  publication-title: Scand J Gastroenterol
  doi: 10.3109/00365521.2011.574732
– volume: 398
  start-page: 1894
  year: 2021
  ident: ref80
  article-title: Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01789-X
– volume: 372
  start-page: 2509
  issue: 26
  year: 2015
  ident: ref47
  article-title: PD-1 blockade in tumors with mismatch-repair deficiency
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1500596
– volume: 28
  start-page: 1325
  issue: 06
  year: 2017
  ident: ref60
  article-title: Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx125
– volume: 26
  start-page: 2006
  issue: 12
  year: 2008
  ident: ref68
  article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.9898
– volume: 21
  start-page: 630
  issue: 01
  year: 2021
  ident: ref5
  article-title: Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08398-z
– volume: 370
  start-page: 143
  year: 2007
  ident: ref61
  article-title: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61087-3
– volume: 139
  start-page: 81
  year: 2020
  ident: ref120
  article-title: Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2020.08.009
– volume: 26
  start-page: 259
  issue: 04
  year: 2005
  ident: ref27
  article-title: Imaging for predicting the risk factors–the circumferential resection margin and nodal disease–of local recurrence in rectal cancer: a meta-analysis
  publication-title: Semin Ultrasound CT MR
  doi: 10.1053/j.sult.2005.04.005
– volume: 329
  start-page: 1271
  issue: 15
  year: 2023
  ident: ref93
  article-title: Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2023.4428
– volume: 7
  start-page: 380
  issue: 03
  year: 2016
  ident: ref168
  article-title: Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2016.03.02
– volume: 11
  start-page: 91
  issue: 02
  year: 2021
  ident: ref2
  article-title: Incidence of colorectal cancers in India: a review from population-based cancer registries
  publication-title: Curr Med Res Pract
  doi: 10.4103/cmrp.cmrp_65_20
– volume: 17
  start-page: 738
  issue: 06
  year: 2016
  ident: ref55
  article-title: Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00150-9
– volume: 38
  start-page: 116
  year: 2020
  ident: ref153
  article-title: Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.4_suppl.116
– volume: 17
  start-page: 687
  issue: 06
  year: 2019
  ident: ref77
  article-title: Geriatric assessment, not ASA physical status, is associated with 6-month postoperative survival in patients with cancer aged ≥75 years
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2018.7277
– volume: 22
  start-page: 779
  issue: 06
  year: 2021
  ident: ref102
  article-title: Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00086-3
– volume: 26
  start-page: 5705
  issue: 35
  year: 2008
  ident: ref44
  article-title: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.0786
– volume: 246
  start-page: 916
  issue: 06
  year: 2007
  ident: ref31
  article-title: Long-term results of intersphincteric resection for low rectal cancer
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e31815c29ff
– volume: 23
  start-page: 659
  issue: 05
  year: 2022
  ident: ref111
  article-title: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(22)00197-8
– volume: 24
  start-page: 394
  issue: 03
  year: 2006
  ident: ref103
  article-title: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.0106
– volume: 23
  start-page: 4866
  issue: 22
  year: 2005
  ident: ref65
  article-title: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.07.113
– volume: 7
  start-page: 10426
  issue: 01
  year: 2017
  ident: ref142
  article-title: Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-11048-9
– volume: 146
  start-page: 29
  year: 2020
  ident: ref114
  article-title: Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2020.02.008
– volume: 42
  start-page: LBA768
  year: 2024
  ident: ref112
  article-title: Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2024.42.3_suppl.LBA768
– volume: 33
  start-page: 1809
  issue: 16
  year: 2015
  ident: ref43
  article-title: Metastatic colorectal cancer: current state and future directions
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.7633
– volume: 38
  start-page: e16084
  year: 2020
  ident: ref3
  article-title: Trends in colorectal cancer incidence in India
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.e16084
– volume: 15
  start-page: 713
  issue: 01
  year: 2015
  ident: ref147
  article-title: Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1701-3
– volume: 20
  start-page: 651
  issue: 11
  year: 2020
  ident: ref169
  article-title: A guide to cancer immunotherapy: from T cell basic science to clinical practice
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0306-5
– volume: 18
  start-page: 1004
  issue: 09
  year: 2013
  ident: ref100
  article-title: Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2013-0107
– volume: 5
  start-page: 182
  issue: 04
  year: 2016
  ident: ref167
  article-title: Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
  publication-title: South Asian J Cancer
  doi: 10.4103/2278-330X.195338
– volume: 3
  start-page: 211
  issue: 02
  year: 2017
  ident: ref84
  article-title: Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.4227
– volume: 25
  start-page: 137
  issue: 01
  year: 2024
  ident: ref23
  article-title: MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(23)00572-7
– volume: 118
  start-page: 54
  year: 2017
  ident: ref75
  article-title: Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2017.08.006
– volume: 8
  start-page: 484
  issue: 04
  year: 2017
  ident: ref4
  article-title: Colorectal cancer in India: an audit from a tertiary center in a low prevalence area
  publication-title: Indian J Surg Oncol
  doi: 10.1007/s13193-017-0655-0
– volume: 36
  start-page: 726
  year: 2018
  ident: ref91
  article-title: Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.4_suppl.726
– volume: 103
  start-page: 210
  issue: 02
  year: 2018
  ident: ref166
  article-title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.911
– volume: 17
  start-page: 1426
  issue: 10
  year: 2016
  ident: ref122
  article-title: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30269-8
– volume: 378
  start-page: 731
  issue: 08
  year: 2018
  ident: ref59
  article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1714448
– volume: 32
  start-page: LBA387
  year: 2014
  ident: ref34
  article-title: Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2014.32.3_suppl.lba387
– volume: 94
  start-page: 798
  issue: 06
  year: 2006
  ident: ref74
  article-title: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603011
– volume: 7
  start-page: 11380
  issue: 10
  year: 2016
  ident: ref145
  article-title: Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7193
– volume: 14
  start-page: 1077
  issue: 11
  year: 2013
  ident: ref98
  article-title: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70154-2
– volume: 11
  start-page: 293
  issue: 04
  year: 2022
  ident: ref6
  article-title: Treatment of metastatic colorectal cancers in resource-constrained low- and middle-income countries (LMICS) scenario-outcomes, practice patterns, and commentary on treatment costs
  publication-title: South Asian J Cancer
  doi: 10.1055/s-0041-1736203
– volume: 13
  start-page: 1178772
  year: 2023
  ident: ref49
  article-title: Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases
  publication-title: Front Oncol
  doi: 10.3389/fonc.2023.1178772
– volume: 39
  start-page: 611
  issue: 01
  year: 2022
  ident: ref126
  article-title: Stereotactic body radiation therapy for colorectal liver metastases
  publication-title: Int J Hyperthermia
  doi: 10.1080/02656736.2021.1923836
– volume: 30
  start-page: 370
  issue: 01
  year: 2020
  ident: ref21
  article-title: Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging
  publication-title: Eur Radiol
  doi: 10.1007/s00330-019-06369-4
– volume: 24
  start-page: 496
  issue: 05
  year: 2023
  ident: ref57
  article-title: Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(23)00150-X
– volume: 14
  start-page: 29
  issue: 01
  year: 2013
  ident: ref135
  article-title: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70477-1
– volume: 178
  start-page: 282
  issue: 04
  year: 1999
  ident: ref19
  article-title: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
  publication-title: Am J Surg
  doi: 10.1016/S0002-9610(99)00187-7
– volume: 21
  start-page: 2059
  issue: 11
  year: 2003
  ident: ref132
  article-title: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.11.126
– volume: 13
  start-page: 1268783
  year: 2023
  ident: ref163
  article-title: The value of carcinoembryonic antigen stage in staging, prognosis, and management of colorectal cancer: results from two cohort studies
  publication-title: Front Oncol
  doi: 10.3389/fonc.2023.1268783
– volume: 28
  start-page: 1713
  issue: 08
  year: 2017
  ident: ref92
  article-title: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx175
– volume: 28
  start-page: 2932
  issue: 12
  year: 2017
  ident: ref140
  article-title: Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx514
– volume: 385
  start-page: 1843
  year: 2015
  ident: ref105
  article-title: Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)62004-3
– volume: 39
  start-page: 273
  issue: 04
  year: 2021
  ident: ref162
  article-title: Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.02088
– volume: 26
  start-page: 724
  issue: 04
  year: 2015
  ident: ref134
  article-title: Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv012
– volume: 381
  start-page: 303
  year: 2013
  ident: ref149
  article-title: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61900-X
– volume: 35
  start-page: 197
  issue: 04
  year: 2017
  ident: ref22
  article-title: Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases
  publication-title: Jpn J Radiol
  doi: 10.1007/s11604-017-0622-2
– volume: 113
  start-page: 779
  issue: 10
  year: 1990
  ident: ref83
  article-title: Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-113-10-779
– volume: 32
  start-page: 1387
  issue: 04
  year: 2012
  ident: ref124
  article-title: Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
  publication-title: Anticancer Res
– volume: 35
  start-page: 192
  issue: 03
  year: 2014
  ident: ref9
  article-title: Indian Council of Medical Research consensus document for the management of colorectal cancer
  publication-title: Indian J Med Paediatr Oncol
  doi: 10.4103/0971-5851.142031
– volume: 206
  start-page: 755
  issue: 03
  year: 1998
  ident: ref17
  article-title: Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings
  publication-title: Radiology
  doi: 10.1148/radiology.206.3.9494497
– volume: 43
  start-page: 440
  issue: 04
  year: 2008
  ident: ref26
  article-title: Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520701745842
– volume: 9
  start-page: 3099
  year: 2015
  ident: ref160
  article-title: Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S85567
– volume: 360
  start-page: 563
  issue: 06
  year: 2009
  ident: ref40
  article-title: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0808268
– volume: 25
  start-page: 1670
  issue: 13
  year: 2007
  ident: ref73
  article-title: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.0928
– volume: 42
  start-page: 3967
  issue: 33
  year: 2024
  ident: ref82
  article-title: Oxaliplatin added to fluoropyrimidine/bevacizumab as initial therapy for unresectable metastatic colorectal cancer in older patients: a multicenter, randomized, open-label phase III trial (JCOG1018)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.23.02722
– volume: 25
  start-page: 1658
  issue: 13
  year: 2007
  ident: ref157
  article-title: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.1620
– volume: 26
  start-page: 1626
  issue: 10
  year: 2008
  ident: ref33
  article-title: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.7116
– volume: 350
  start-page: 2335
  issue: 23
  year: 2004
  ident: ref96
  article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa032691
– volume: 21
  start-page: 412
  issue: 03
  year: 2020
  ident: ref155
  article-title: TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30827-7
– volume: 24
  start-page: 757
  issue: 07
  year: 2023
  ident: ref121
  article-title: First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(23)00219-X
– volume: 14
  start-page: 749
  issue: 08
  year: 2013
  ident: ref45
  article-title: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70163-3
– volume: 26
  start-page: 100
  issue: 02
  year: 2020
  ident: ref115
  article-title: Prognostic and predictive biomarkers in oligometastatic disease
  publication-title: Cancer J
  doi: 10.1097/PPO.0000000000000438
– volume: 359
  start-page: 1757
  issue: 17
  year: 2008
  ident: ref32
  article-title: K-ras mutations and benefit from cetuximab in advanced colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0804385
– volume: 3
  start-page: 194
  issue: 02
  year: 2017
  ident: ref88
  article-title: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.3797
– volume: 32
  start-page: 325
  issue: 01
  year: 2015
  ident: ref136
  article-title: A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0325-9
– volume: 48
  start-page: 28S
  issue: S 01
  year: 2007
  ident: ref16
  article-title: Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care
  publication-title: J Nucl Med
– volume: 15
  start-page: 569
  issue: 06
  year: 2014
  ident: ref159
  article-title: Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70118-4
– volume: 22
  start-page: 256
  issue: 02
  year: 2021
  ident: ref127
  article-title: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30599-4
– volume: 16
  start-page: 619
  issue: 06
  year: 2015
  ident: ref150
  article-title: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)70156-7
– volume: 23
  start-page: 2313
  issue: 09
  year: 2012
  ident: ref148
  article-title: Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdr623
– volume: 34
  start-page: 10
  issue: 01
  year: 2023
  ident: ref7
  article-title: Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2022.10.003
– volume: 352
  start-page: 1413
  year: 1998
  ident: ref129
  article-title: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)02309-5
– volume: 145
  start-page: 576
  issue: 02
  year: 2019
  ident: ref109
  article-title: Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: a retrospective analysis of two randomised trials
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32110
– volume: 15
  start-page: 1827
  issue: 06
  year: 2023
  ident: ref116
  article-title: Oligo-metastatic cancers: putative biomarkers, emerging challenges and new perspectives
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers15061827
– volume: 383
  start-page: 2207
  issue: 23
  year: 2020
  ident: ref52
  article-title: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2017699
– volume: 34
  start-page: 3517
  year: 2016
  ident: ref54
  article-title: HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.34.15_suppl.3517
– volume: 14
  start-page: 1208
  issue: 12
  year: 2013
  ident: ref119
  article-title: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70447-9
– volume: 22
  start-page: 4891
  issue: 20
  year: 2016
  ident: ref24
  article-title: Rectal cancer staging: Multidetector-row computed tomography diagnostic accuracy in assessment of mesorectal fascia invasion
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v22.i20.4891
– volume: 20
  start-page: 518
  issue: 04
  year: 2019
  ident: ref56
  article-title: Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30904-5
– volume: 25
  start-page: 4224
  issue: 27
  year: 2007
  ident: ref66
  article-title: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.09.8467
– volume: 22
  start-page: 934
  issue: 08
  year: 2017
  ident: ref79
  article-title: Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making?
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2016-0462
– volume: 4
  start-page: e173695
  issue: 07
  year: 2018
  ident: ref86
  article-title: Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.3695
– volume: 3
  start-page: 99ra86
  issue: 99
  year: 2011
  ident: ref53
  article-title: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3002442
– volume: 36
  start-page: 674
  issue: 07
  year: 2018
  ident: ref107
  article-title: Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.75.2931
– volume: 71
  start-page: 209
  issue: 03
  year: 2021
  ident: ref1
  article-title: Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 22
  start-page: 813
  issue: 04
  year: 2016
  ident: ref50
  article-title: Microsatellite instability as a biomarker for PD-1 blockade
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1678
– volume: 34
  start-page: 94
  issue: 02
  year: 2016
  ident: ref69
  article-title: XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis
  publication-title: Cancer Invest
  doi: 10.3109/07357907.2015.1104689
– volume: 51
  start-page: 1147
  issue: 10
  year: 2010
  ident: ref10
  article-title: Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines
  publication-title: Clin Infect Dis
  doi: 10.1086/656735
– volume: 370
  start-page: 135
  year: 2007
  ident: ref62
  article-title: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61086-1
– volume: 70
  start-page: 87
  year: 2017
  ident: ref85
  article-title: The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.10.007
– volume: 372
  start-page: 1909
  issue: 20
  year: 2015
  ident: ref154
  article-title: Randomized trial of TAS-102 for refractory metastatic colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1414325
SSID ssj0001033891
ssib050738867
Score 2.3126092
SecondaryResourceType online_first
Snippet Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global...
SourceID doaj
crossref
SourceType Open Website
Index Database
SubjectTerms India specific
metastatic colorectal cancer
modified Delphi consensus
Title Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method
URI https://doaj.org/article/dd75086cb8f84ff5af408cd95e4f1411
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09b9swECXaDEWWIkkT5KM1OBToRJgyPzU6bgyngIoODuBNoPiBGAiUIHa2_PjcUXThLUtWiRKE44H3TuR7j5CfE5jjmtvIKukCNCjeMqjrmqH0VUzVxJkKicLNX724k39WarVn9YVnwgZ54CFw4xCgplntO5usTEm5JLn1oVZRpkoOrF5e871mCjIJQI6wthTW_LeFCzHY5yH1k0ETv9opOCo13jBENgylrATqQ-5VqD0h_1xx5kfka4GKdDp84jH5FPsT8qUpm-HfyCuabaJTxYZmyJjJahRAKC1inw_0X-FA0XVPp2W3f9zErUMe0drTGSx9uOTB0BnefN7gyNsekobmwwTU0eYxrBMAVfo7Pjzdr2mTPadPyXJ-s5wtWDFTYF5IvmVJusyaTsZ6lbxO0PqJ4J2rpQPY46MWptNadqYKyXZe1iY6HlQwXnWpEmfkoH_s4zmh2kDgnQDgEb10ytYOIAA8bI2rjXf8gvzaxa99GiQz2rzVrVS7aTHSbYn0BbnG8P4fhVLX-QIkQFsSoH0vAS4_4iVX5HCCxr4cj_x9Jwfb55f4A9DGthuRz_xOj3J6vQHoi8_S
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Consensus+Statements+for+Clinical+Practice+in+Advanced%2FMetastatic+Colorectal+Cancers+in+India+Using+a+Modified+Delphi+Method&rft.jtitle=South+Asian+journal+of+cancer&rft.au=Ramaswamy%2C+Anant&rft.au=Srinivas%2C+Sujay&rft.au=Lavingia%2C+Viraj&rft.au=Boppana%2C+Mounika&rft.date=2025-05-26&rft.issn=2278-330X&rft.eissn=2278-4306&rft_id=info:doi/10.1055%2Fs-0045-1809380&rft.externalDBID=n%2Fa&rft.externalDocID=10_1055_s_0045_1809380
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2278-330X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2278-330X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2278-330X&client=summon